AMPEL BIOSOLUTIONS WAS FOUNDED TO BRING PERSONALIZED PRECISION MEDICINE TO PATIENTS, ESPECIALLY THOSE SUFFERING FROM AUTOIMMUNE AND INFLAMMATORY DISEASES.
Autoimmune and inflammatory disease patients are not receiving the precise, personalized evaluation and treatment that they deserve. The immune system of autoimmune patients is complex, dynamic and not accurately assessed by current technology.
The AMPEL team brings their expertise in basic and translational research, clinical trial design, and bioinformatics together in a new way to develop scalable systems using AI and deep machine learning to improve patient outcomes. To give patients and their doctors the tools and information necessary to make decisions based on that individual’s genomic profile — what we term their Genomic Fingerprint.
Your Genes have a lot to tell you!
We can be your translator.
AMPEL BioSolutions identifies your Genomic Fingerprint®️
providing personalized precision medicine.
AMPEL’s LuGENE®️ approach suggests existing FDA-approved drugs that could be repositioned, or repurposed, to interfere with the autoimmune or inflammatory response.
Starting with a simple lab blood draw AMPEL analyzes patient RNA for gene expression that predicts disease activity and best drug option(s) using our bioinformatic tools on AMPEL’s Genomic Platform (AGP®️). Results are summarized in a physician’s report. LuGENE®️ provides a greater understanding of an individual’s current inflammatory/autoimmune profile, genomic fingerprint.
LEARN MORE
After a medical team has a better understanding of a patient’s inflammatory response, it’s time for therapeutic interventions. AMPEL’s LuGENE®️ approach identifies existing FDA-approved drugs that could be repositioned, or repurposed, to interfere with the autoimmune or inflammatory response.
After a medical team has a better understanding of a patient’s inflammatory response, it’s time for therapeutic interventions. AMPEL’s CovGENETM approach identifies existing FDA-approved drugs that could be repositioned, or repurposed, to interfere with cytokine storms, macrophage activation, and other mechanisms that lead to severe lung damage.
Lightning talk session by Dr. Amrie Grammer, Ph.D. Personalized Precision Medicine: Matching the Right Drug with the Right Patient at the Right Time
Machine Learning Approaches to Predict Lupus Disease Activity from Gene Expression Data The integration of gene expression data to predict systemic lupus erythematosus (SLE) disease activity is a significant challenge because of the high degree of heterogeneity among patients and
At BioBuzz, we’re dedicated to bringing you interesting and important stories that emerge from the thriving life sciences ecosystem that is the BioHealth Capital Region (BHCR). The heart of the BHCR biohealth cluster is Maryland, with its vast network of
About AMPEL BioSolutions
AMPEL BioSolutions was founded to bring personalized precision medicine to patients with diseases involving the immune system and inflammation. In 2022, AMPEL expects to commercialize it’s first product, a CLIA-certified blood test for patients/physicians called LuGENE® that assesses disease state/flares and best drug option(s). AMPEL’s technology covers >95% of all known genes and is disease agnostic so there is capacity to expand reporting of results into new disease indications without developing a new test. AMPEL’s exclusive curated database of >10,000 Lupus patient gene expression profiles with rich clinical information is the world’s largest and fuels machine learning predictions based on evidence. AMPEL’s current customers are Pharma/Biotech for design/management Lupus clinical trials and patient stratification using it’s proprietary genomic platform, bioinformatic tools and ML/AI algorithms.
AMPEL’s co-founders, Amrie Grammer and Peter Lipsky, are internationally recognized scientists and successful entrepreneurs, having founded and managed AMPEL to profitability consistently for 5+ years. Their success has been a combination of world-class science with business acumen. Dr. Grammer was elected to the class of 2021 of SIBF (Society of International Business Fellows), an organization of 1400 in 45 countries world-wide and was awarded a Virginia SBIG grant from AMPEL’s first investment round. She is a second term board member of Virginia Bio.
Before co-founding AMPEL in 2013, Dr. Lipsky was the Director of the Intramural Research Program and the Autoimmunity Branch of NIAMS at the NIH. Peter’s career has been distinguished by multiple scientific awards including the Carol Nachman Prize, the American College of Rheumatology Distinguished Investigator Award and the Arthritis Foundation’s prestigious Lee Howley prize. Dr. Grammer has over 20+ years experience in genomics and managed a highly productive NIH laboratory before co-founding AMPEL. Dr. Grammer received multiple awards for her team’s work comparing genes expressed in patients compared with healthy individuals, including the prestigious Director’s Award and mentoring awards from the American Association of Immunologists. AMPEL’s work has been featured at the Precision Medicine World Conference and at the Biotech Showcase of JP Morgan.
Contract with AMPEL for patient stratification and pre-clinical model work. AMPEL uses it’s genomic platform, bioinformatic tools and machine learning algorithms to assist with real-time patient screening during clinical trial enrollment and pipeline assessment.
For more information, please fill out the form below.
You can also call (434) 296-AMPL (2675) or email us at info@ampel.org.